Aussies continue FDA winning streak
The FDA has granted an orphan drug designation to Melbourne-based Neuren Pharmaceuticals for NNZ-2591 for the treatment of neonatal hypoxic-ischemic encephalopathy (HIE) in what the company has described as a significant commercial milestone.
To see the whole article, log in or create an account.